The "Peanut Allergy - Pipeline Insight, 2025" has been added to ResearchAndMarkets.com's offering.

The "Peanut Allergy - Pipeline Insight, 2025" report delivers in-depth analysis of the Peanut Allergy therapeutic landscape, highlighting over 10 companies and upwards of 12 pipeline drugs.

This report encompasses detailed drug profiles across clinical and nonclinical stages, with assessments categorized by product type, stage, route of administration, and molecule type. Moreover, it touches on inactive pipeline products, providing a comprehensive view of the current scenario and future growth prospects in Peanut Allergy treatments.

Peanut allergy is a significant focus due to its prevalence and potential severity, often leading to severe reactions such as anaphylaxis. Although strict eradication of peanuts from the diet is advised, the pervasive presence of trace peanut residues makes total avoidance difficult, propelling the need for research toward innovative therapies. Immunotherapies and vaccine-based strategies are being developed to enhance tolerance and patient safety.

The report underscores groundbreaking therapies under development, including immunotherapy and vaccine strategies aimed at desensitizing the immune system. Notable drugs like DBV Technologies' DBV712 (in Phase III) target epicutaneous immunotherapy, offering a non-invasive daily treatment option. Aravax Pty Ltd's PVX-108, in Phase II, utilizes peptide sequences to retrain the immune system without requiring dose escalation, presenting a potential long-term solution with a low risk of severe reactions. InnoUp Farma S.L.'s INP20, currently in Phase I/II, leverages nanoparticle technology to provide controlled-release treatment directly to the gut, minimizing systemic absorption and reducing the risk of allergenic response.

The report thoroughly categorizes these drugs by various parameters such as product phase and route of administration, including oral, topical, and subcutaneous applications. Additionally, it segments according to molecule type, including recombinant fusion proteins, peptides, and gene therapies, reflecting the diverse approaches in addressing Peanut Allergy.

Furthermore, the report delves into detailed commercial and clinical assessments of the pipeline products, covering technology development, partnerships, licensing activities, and significant collaborations that could shape the future of Peanut Allergy therapeutics. Industry movements such as mergers, funding initiatives, and product development documents are also analyzed to present a full picture of the market dynamics.

Highlighted players in this space include DBV Technologies, Aravax Pty Ltd, and InnoUp Farma S.L., among others, advancing innovative solutions to meet the unmet needs in Peanut Allergy management. The report evaluates pipeline product profiles, therapeutic assessments, and the anticipated impact of emerging therapies, offering insights into the changing landscape of Peanut Allergy treatment.

Key questions addressed include the current number of drugs being developed, stages of development, partnerships shaping the industry, and recent technological advancements. The report positions itself as a robust resource for understanding the Peanut Allergy pipeline and prospective treatment modalities. As research progresses, the report promises regular updates on clinical studies, emerging trends, key collaborations, and market analyses impacting stakeholders in this field.

Key Topics Covered:

Introduction

Executive Summary

Peanut Allergy: Overview

• Introduction
• Causes
• Pathophysiology
• Signs and Symptoms
• Diagnosis
• Treatment

Pipeline Therapeutics

• Comparative Analysis

Therapeutic Assessment

• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

Peanut Allergy - Analytical Perspective

Late Stage Products (Phase III)

• Comparative Analysis

DBV712: DBV Technologies

• Product Description
• Research and Development
• Product Development Activities

Mid Stage Products (Phase II)

• Comparative Analysis

PVX-108: Aravax Pty Ltd

• Product Description
• Research and Development
• Product Development Activities

Early Stage Products (Phase I/II)

• Comparative Analysis

INP20: InnoUp Farma S.L.

• Product Description
• Research and Development
• Product Development Activities

Preclinical and Discovery Stage Products

• Comparative Analysis

Drug Name: Company Name

• Product Description
• Research and Development
• Product Development Activities

Inactive Products

• Comparative Analysis

Peanut Allergy Key Companies

Peanut Allergy Key Products

Peanut Allergy - Unmet Needs

Peanut Allergy - Market Drivers and Barriers

Peanut Allergy - Future Perspectives and Conclusion

Peanut Allergy Analyst Views

Peanut Allergy Key Companies

• DBV Technologies
• Aravax Pty Ltd
• InnoUp Farma S.L.
• Allergy Therapeutics
• ALK-AbellA A/S
• IgGenix Australia Pty Ltd

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/yxcynz

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250801817010/en/